RET kinase inhibitors: a review of recent patents (2012-2015)

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Tyrosine kinases, including RET kinase, are critical in cellular processes and are frequent targets in cancer therapy.
• Dysregulated RET kinase activity drives thyroid and lung cancers, necessitating targeted therapeutic strategies.
• Current treatments for RET-driven cancers have limitations, highlighting the need for improved inhibitors.

Purpose of the Study:

• To review recent patent literature (2012-2015) on compounds targeting RET kinase.
• To identify emerging next-generation anti-RET drugs.
• To assess the potential of novel compounds for treating RET-driven malignancies.

Main Methods:

• Literature review of patent filings from 2012-2015.
• Analysis of compounds described in patents for their activity against RET kinase.
• Evaluation of the therapeutic potential of identified compounds.

Main Results:

• The patent literature reveals ongoing development of novel RET kinase inhibitors.
• Several new compounds are under preclinical and clinical investigation.
• These emerging drugs aim for increased potency and specificity compared to existing therapies.

Conclusions:

• Despite existing treatments, there remains a significant need for more effective and specific RET inhibitors.
• The reviewed patents showcase promising next-generation compounds that could address this unmet need.
• Future therapies may benefit from these novel, specifically designed anti-RET agents.